FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor

Experimental Cell Research
H NakajimaS Horinouchi

Abstract

Screening for microbial metabolites that induce transcriptional activation of the SV40 promoter resulted in the identification of two known compounds, FR901228 and trichostatin A (TSA). FR901228 is a potent antitumor drug that is currently under clinical investigation. TSA is a specific inhibitor of histone deacetylase. Despite structural unrelatedness, both FR901228 and TSA greatly enhanced the transcriptional activity of the SV40 promoter in an enhancer-dependent manner. The effects of FR901228 on the cell cycle, chromatin structure, and histone acetylation were examined and compared with those of TSA. Both compounds caused arrest of the cell cycle at both G1 and G2/M phases and induction of internucleosomal breakdown of chromatin. FR901228, like TSA, inhibited intracellular histone deacetylase activity, as a result of which marked amounts of acetylated histone species accumulated. FR901228 is therefore a new type of histone deacetylase inhibitor, whose chemical structure is unrelated to known inhibitors such as trichostatins and trapoxins.

References

Jan 1, 1976·The Journal of Antibiotics·N TsujiK Koizumi
Jan 1, 1992·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·E M Bradbury
May 29, 1992·Biochemical and Biophysical Research Communications·M J Hendzel, J R Davie
Aug 1, 1991·The Biochemical Journal·G Golderer, P Gröbner
Feb 1, 1991·The Biochemical Journal·M J Hendzel, J R Davie
Nov 11, 1970·Biochimica Et Biophysica Acta·A Inoue, D Fujimoto
May 1, 1995·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·M YoshidaT Beppu
Sep 15, 1994·European Journal of Biochemistry·V GirardotS Khochbin
May 24, 1994·Proceedings of the National Academy of Sciences of the United States of America·M J BarrattL C Mahadevan
Aug 1, 1995·Seminars in Cell Biology·B M Turner, L P O'Neill
Apr 15, 1996·Genes & Development·R E KingstonA N Imbalzano
Sep 5, 1996·Nature·R Janknecht, T Hunter
Dec 10, 1996·Proceedings of the National Academy of Sciences of the United States of America·S E RundlettM Grunstein
Dec 19, 1996·Nature·A J Bannister, T Kouzarides
May 27, 1997·Proceedings of the National Academy of Sciences of the United States of America·W Y ChenT M Townes
Feb 1, 1993·Roux's Archives of Developmental Biology : the Official Organ of the EDBO·Susumu IkegamiTeruhiko Beppu

❮ Previous
Next ❯

Citations

May 29, 2007·Chemical Reviews·Patrick J WalshCecilia Anaya de Parrodi
May 18, 2005·Oncogene·Thiyam Ramsing SinghRakesh K Srivastava
Nov 21, 2002·Journal of Experimental Therapeutics & Oncology·John L MarshallMichael J Hawkins
Nov 3, 2001·Molecular Urology·Y Kaneda
Jun 14, 2003·Journal of Hematotherapy & Stem Cell Research·Alice NemajerováJana Smardová
Nov 29, 2012·Thyroid : Official Journal of the American Thyroid Association·Eric J ShermanDavid G Pfister
Dec 18, 2002·The EMBO Journal·Akihisa MatsuyamaMinoru Yoshida
Aug 3, 2000·Journal of the National Cancer Institute·P A MarksR A Rifkind
Aug 24, 2005·Acta Pharmacologica Sinica·Danila Coradini, Annalisa Speranza
Feb 10, 2000·Annals of the New York Academy of Sciences·M Yoshida, S Horinouchi
Jan 11, 2000·Journal of Medical Genetics·C A Johnson
Mar 1, 2011·Blood·Richard L PiekarzSusan E Bates
Oct 31, 2008·BMC Genomics·Sridar V ChitturPaulette J McCormick
Nov 11, 2003·BMC Cancer·José Manuel Afonso MoreiraPoul Sørensen
Nov 15, 2003·Reproductive Biology and Endocrinology : RB&E·X Cindy TianXiangzhong Yang
Jun 3, 2009·Journal of Hematology & Oncology·Shundong CangDelong Liu
Oct 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard L PiekarzSusan E Bates
Sep 13, 2008·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Hidenori Nakajima
Jul 16, 2008·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Minoru Yoshida
Sep 14, 2010·The Journal of Reproduction and Development·Min-Jung LeeDong-Hoon Kim
Mar 16, 2012·Future Medicinal Chemistry·Sophia RangwalaMadeleine Duvic
Apr 12, 2013·Future Medicinal Chemistry·Sarah K BurroughsBinghe Wang
Jan 15, 2011·Journal of Biomedicine & Biotechnology·Anne M BestElisabeth D Martinez
Jul 19, 2014·Nature Reviews. Drug Discovery·John G MoffatDavid Bailey
Jul 12, 2005·Expert Opinion on Investigational Drugs·Jennifer S Isaacs
Mar 9, 2011·Expert Opinion on Investigational Drugs·Ernesto VignaFortunato Morabito
Sep 14, 2015·Journal of Industrial Microbiology & Biotechnology·Junghwa Chang, Ho Jeong Kwon

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.